

Prediction and analysis of HLA-A2/A24-restricted cytotoxic T-lymphocyte epitopes of the tumor antigen MAGE-n using the artificial neural networks method on NetCTL1.2 Server

XIU-MIN ZHANG^{1*}, YANG HUANG^{2*}, ZENG-SHAN LI¹, HUI LIN¹ and YAN-FANG SUI¹

¹State Key Laboratory of Cancer Biology, Department of Pathology, and ²Department of Emergency Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China

Received July 29, 2010; Accepted September 17, 2010

DOI: 10.3892/ol.2010.193

Abstract. Cancer immunotherapy has become one of the most important therapeutic approaches to cancer in the past two decades. Tumor antigen-derived peptides have been widely used to elicit tumor-specific cytotoxic T lymphocytes (CTLs). Antigen-specific CTLs induced by MAGE-derived peptides have proven to be highly efficacious in the prevention and treatment of various types of tumor. MAGE-n is a new member of the MAGE gene family and has been shown to be closely associated with hepatocellular carcinoma. It is highly homologous to the MAGE-A gene subfamily, particularly to MAGE-3 (93%). MAGE-n-derived peptide QLVFGIEVV is a novel HLA-A2.1-restricted CTL epitope that induces MAGE-n-specific CTLs *in vitro*. Identification of these CTL epitopes may lead to clinical applications of these peptides as cancer vaccines for patients with MAGE-n⁺/HLA-A2⁺ tumors. In the present study, HLA-A/A24-restricted CTL epitopes of antigen MAGE-n were predicted using the NetCTL1.2 Server on the web, COMB >0.85. The results showed that the NetCTL1.2 Server prediction method improved prediction efficacy and accuracy. Additionally, 8 HLA-A2- and 9 HLA-A24-restricted CTL epitope candidates (nonamers) derived from the tumor antigen MAGE-n were predicted. These nonamers, following identification via experimentation, may contribute to the development of potential antigen peptide tumor vaccines.

Introduction

Recent studies have shown that tumor antigens, particularly tumor-specific antigens, which induce tumor-specific cytotoxic

T lymphocytes (CTLs) and damage tumor cells, are a significant component of tumor vaccines. Epitope peptide vaccine has been of particular interest as it induces specific CTL *in vitro* and *in vivo* in order to kill target cells. Previously, a number of human genes that code for tumor antigens identified by autologous CTLs were isolated (1,2), and the epitopes derived from these tumor antigens were further identified to serve as targets for CTLs in the context of HLA class I molecules (3). MAGE-n is a newly identified member of the MAGE gene family which was first reported by our laboratory (Genebank, locus no. AF443295) (4), and was also found to be highly homologous to MAGE-A subfamily genes. Since HLA-A2/A24 is one of the most frequently expressed molecules in the Chinese population (5,6), it is crucial to identify the tumor antigen epitopes which are presented by HLA-A2/A24 and to induce epitope-specific CTLs against tumor cells. The present study reported a simple and efficient bioinformatics method to identify candidate HLA-A2/A24-restricted CTL epitopes from the tumor antigen MAGE-n.

Materials and methods

MAGE-n (316 aa) was selected as the antigen of interest in this study. The amino acid sequences of the tumor antigen were obtained from the Genbank database: MSLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSTLVEVTLGEVPAESPDPQPQSGASSLP TTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQ AALSRKVAELVHFLLLKYRAREPFTKAEMLGS VIRNFQDFFPVIFSEASEYLQLVFGIEVVEVV RIGHLIYLVTCGLSYDGLLDGDNQIMPKTGFLIIVLV MIAMEGGHAPEEEIWEELSVMEVYDGREHSAY GEPRKLLTQDLVQEKYLEYRQVPDSDPARYEFL WGPLRALAETSYVKVLEYVIKVSARVRFFFPSLREAA LREEEEGV.

Methods. HLA-A/A24-restricted CTL epitopes of antigen MAGE-n were predicted using the NetCTL1.2 Server on the web. The NetCTL1.2 Server (<http://www.cbs.dtu.dk/services/NetCTL>) was used for CTL epitope prediction according to the following steps: i) input (paste) the MAGE-n protein sequence in the 'Submission' window, ii) select A2/A24 (HLA-A2/

Correspondence to: Dr Yan-Fang Sui, State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China
E-mail: suiyanf@gmail.com

*Contributed equally

Key words: MAGE-n, HLA-A2/A24, cytotoxic T-lymphocyte epitope, prediction

Instructions	Output format	Data sets
--------------	---------------	-----------

SUBMISSION

Paste a single sequence or several sequences in *FASTA* format into the field below:

```

LGDNQIMPKTGFLIIIVLVMIAIEGGHAPPEEIIWEELSVMEVYDGRHSAYGEPKLLTQDLVQ
EKYLEYRQVPDSDPARYEFLWGPRLAETS YVKVLEYV I KVSARV RFFFP SLREAAALREEEEG
V
  
```

Submit a file in *FASTA* format directly from your local disk:

Supertype

Weight on C terminal cleavage Weight on TAP transport efficiency Threshold for epitope identification

Sort by score

Restrictions:
At most 5000 sequences per submission; each sequence not more than 20,000 amino acids and not less than 9 amino acids.

Confidentiality:
The sequences are kept confidential and will be deleted after processing.

Figure 1. The web page of the NetCTL-1.2 Server epitope prediction.

Table I. HLA-A2-restricted epitope prediction results derived from MAGE-n.

ID	Sequence pep	aff	aff_rescale	cle	tap	COMB
201	FLIIVLMI	0.6883	1.0260	0.9554	0.4980	1.1942
176	YILVTCLGL	0.6209	0.9255	0.9451	1.1290	1.1237
289	YVIKVSARV	0.6177	0.9208	0.9484	0.3350	1.0798
108	ALSRKVAEL	0.5660	0.8437	0.9285	1.2680	1.0464
174	HLIYILVTCL	0.5486	0.8178	0.9762	1.0400	1.0163
158	LQLVFGIEV	0.5876	0.8760	0.4210	0.3600	0.9571
276	RALAETSYV	0.5436	0.8103	0.1751	0.4840	0.8608
24	GLVGAQAPA	0.5000	0.7453	0.9252	-0.5690	0.8556

ID, protein identifier; sequence pep, peptide sequence; aff, predicted MHC binding affinity; aff_rescale, rescale binding affinity; cle, C terminal cleavage affinity; tap, TAP transport efficiency; COMB, prediction score.

Table II. HLA-A24-restricted epitope prediction results derived from MAGE-n.

ID	Sequence pep	aff	aff_rescale	cle	tap	COMB
156	EYLQLVFGI	0.7953	1.6935	0.2612	0.6670	1.7661
195	IMPKTGFLI	0.6701	1.4269	0.0687	0.6150	1.4679
293	VSARVRFFF	0.5493	1.1698	0.1103	2.7550	1.3240
97	TFPDLESEF	0.4816	1.0254	0.9542	2.7200	1.3045
76	NYPLWSQSY	0.3996	0.8510	0.9783	3.2470	1.1601
142	NFQDFFPVI	0.4356	0.9276	0.7956	0.8390	1.0889
138	SVIRNFQDF	0.3807	0.8106	0.5758	2.7650	1.0353
282	SYVKVLEYV	0.4190	0.8923	0.4156	0.7200	0.9906
113	VAELVHFLI	0.3159	0.6727	0.9570	1.0260	0.8676

ID, protein identifier; sequence pep, peptide sequence; aff, predicted MHC binding affinity; aff_rescale, rescale binding affinity; cle, C terminal cleavage affinity; tap, TAP transport efficiency; COMB, prediction score.

A24) from the 'Supertype' menu, iii) enter 0.15, 0.05, 1.0 in the 'Weight on C terminal cleavage', 'Weight on TAP transport efficiency' and 'Threshold for epitope identification' windows, respectively, iv) select Combined score from the dropdown menu of 'Sort by score', and v) Submit to run the remote forecast. The predicted value includes the ID (protein identifier), sequence pep (peptide sequence), aff (predicted MHC binding affinity), aff_rescale (rescale binding affinity), cle (C terminal cleavage affinity), tap (TAP transport efficiency) and COMB (prediction score). According to the characteristic property, the greater the COMB, the higher the specificity of the predicted result; 0.85 was selected as the threshold. Finally, the candidate HLA-A2/A24-restricted CTL epitope peptides were obtained by excluding the peptides already confirmed from the prediction results.

Results

The NetCTL-1.2 prediction values of all possible nonamers of a given protein sequence were added together. The peptides of each protein were selected for further analysis. The primary predicted epitopes were compared to those of previous studies (7-9). It was found that the 4 reported HLA-A2-restricted CTL epitopes, i.e., MAGE-1₂₇₈₋₂₈₆(KVLEYVIKV), MAGE-3₂₇₈₋₂₈₆(KVAELVHFL), AGE-3₂₇₁₋₂₇₉(FLWGPRALV) and MAGE-n₁₅₉₋₁₆₇(QLVFGIEVV) were eliminated from the NetCTL-1.2 prediction results. The epitopes with COMB scores <0.85 were eliminated from the prediction results. A total of 8 HLA-A2- and 9 HLA-A24-restricted CTL epitope candidates (nonamers) derived from the tumor antigen MAGE-n were predicted. The results of predicted epitopes are shown in Tables I and II, i.e., that the NetCTL1.2 Server prediction method improved prediction efficacy and accuracy.

Discussion

Recently, with the innovation of immunology methodology, the molecular mechanisms of tumor antigen presentation and CD8⁺ T-cell activation have been gradually elucidated. Tumor antigens and their coding genes have been identified in a consecutive manner. The breakthrough in theoretical tumor immunity has accelerated the development of vaccines targeting tumor antigens. The induction of antigen-specific CTLs has been suggested to be highly efficacious in the prevention and treatment of various types of tumor. Induction of potent anti-tumor CTL responses results in the regression and prevention of metastasis formation, as shown in experimental model tumor systems (10,11). Thus, efforts towards the development of cancer immunotherapy have recently focused on the generation of tumor-specific T-cell responses.

Epitope prediction was recently conducted in tumor antigen specificity for CTL epitope identification in a majority of studies. Approximately 120 CTL epitopes presented by HLA-A, B and C molecules were reported (12), and various epitopes were used as peptide vaccines in animal and clinical experiments (13,14). Schirle *et al* reported that two new CTL epitopes of gastrointestinal tumors were identified by epitope prediction combined with acid elution methods (15).

Dong *et al* found that MAGE-n-derived peptide QLVFGIEVV was a new HLA-A2.1-restricted CTL epitope that induces MAGE-n-specific CTLs *in vitro* (9). Identification of these CTL epitopes allows for clinical applications of these peptides as cancer vaccines for patients with MAGE-n⁺/HLA-A2⁺ tumors. Our previous study showed that the combination of MAGE-3 and MAGE-n epitopes induced more effective anti-tumor immune responses than either of the peptides alone (16). In addition, the peptide-specific activity was observed to be in a MHC-restricted manner. This study suggested that the combination of a number of tumor antigen-derived peptides is more efficacious as a peptide-based cancer immunotherapy.

The combination of epitope prediction, epitope reconstruction and immunological methods improves the efficacy and accuracy of CTL epitope studies (9). The identification of human tumor-rejection antigens and CTL epitopes of these antigens allows for the development of new cancer vaccines since patients are likely to benefit from immunization with an identified CTL epitope. Among the identified tumor-rejection antigens, MAGE gene products are of particular interest due to their wide expression in various types of tumor and their potential to induce tumor-specific CTL responses. A previous study showed that a vaccine with 5 common HLA-I-restricted epitopes was beneficial in 80-90% of patients (17). It was also found that 8-9 common HLA-I-restricted epitopes may exhibit beneficial effects on patients worldwide (17). The identification of the HLA-A2-restricted CTL epitopes from melanoma antigen MAGE-n is crucial. In the present study, the HLA-A2/A24-restricted CTL epitopes of MAGE-n were predicted using the methods from the NetCTL1.2 Server. These candidate epitopes were selected for further immunology experiments. The results showed that the NetCTL1.2 Server prediction method improves prediction efficacy and accuracy. These nonamers, following identification through experimentation may contribute to the development of potential antigen peptide tumor vaccines.

Acknowledgements

This study was supported by grants from the China National Natural Science Foundation (no. 30901735) and the Science and Technology Project of Shaanxi Province, China [no. 2007K09-05(2)].

References

1. Katsura F, Eura M, Chikamatsu K, Oiso M, Yumoto E and Ishikawa T: Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. *Jpn J Clin Oncol* 30: 117-121, 2000.
2. Boel P, Wildmann C, Sensi ML, Brasseur R, Renaud JC, Coulie P, Boon T and van der Bruggen P: BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. *Immunity* 2: 167-175, 1995.
3. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. *Cancer Immunol Immunother* 50: 3-15, 2001.
4. Wu W, Sui YF, Ye J, Li ZS, Guo AL, Yang XW, QU P and Zhang XM: The cloning of tumor-associated gene MAGE in human hepatocellular carcinoma cell line. *Chin J Cell Mol Immunol* 18: 270-274, 2002.
5. Ming LH, Zhu YR, Harris CC, Wang XH, Wu ZY and Sun ZT: Association of HLA-A02 genotype with hepatocellular carcinoma in a prevalent area of China. *Chin J Immunol* 15: 305-310, 1999.

6. Cai SL, Zhao HT, Leng XS, Cheng TH, Gong SY, Peng JR, Cong X, Wang Y, Rui JA, Hui YZ, Du RY and Chen WF: Melanoma antigen-3 expression in human hepatocellular carcinoma. *Chin J Surg* 38: 693-696, 2000.
7. Pascolo S, Schirle M, Guckel B, Dumrese T, Stumm S, Kayser S, Moris A, Wallwiener D, Rammensee HG and Stevanovic S: A MAGE-A1 HLA-A*0201 epitope identified by mass spectrometry. *Cancer Res* 61: 4027-4077, 2001.
8. Vander Bruggen P, Bastin J, Boon T, Gajewski T, Coulie PG, Boël P, De Smet C, Traversari C, Townsend A and Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. *Eur J Immunol* 24: 3038-3043, 1994.
9. Dong HL, Li ZS, Ye J, Qu P, Huang YY, Wu W, Lu SY, Chen GS and Sui YF: Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma. *Cancer Biol Ther* 3: 891-898, 2004.
10. Marchand M, van Baren N, Weynants P, *et al*: Tumor regression observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer* 80: 219-230, 1999.
11. Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K and Murai M: Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. *Clin Cancer Res* 8: 3885-3892, 2002.
12. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberrniedermayr M, Schirmacher V and Umansky V: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. *Nat Med* 7: 452-458, 2001.
13. Dagher R, Long LM, Read EJ, Leitman SF, Carter CS, Tsokos M, Goletz TJ, Avila N, Berzofsky JA, Helman LJ and Mackall CL: Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. *Med Pediatr Oncol* 38: 158-164, 2002.
14. Schiavetti F, Thonnard J, Colau D, Boon T and Coulie PG: A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. *Cancer Res* 62: 5510-5516, 2002.
15. Schirle M, Keilholz W, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanović S and Rammensee HG: Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. *Eur J Immunol* 30: 2216-2225, 2000.
16. Zhang XM, Zhang YF, Huang Y, Qu P, Ma B, Si SY, Li ZS, Li WX, Li X, Ge W, Hu PZ and Sui YF: The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides. *Oncol Rep* 20: 245-252, 2008.
17. Sidney J, Grey HM, Kubo RT and Sette A: Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. *Immunol Today* 17: 261-266, 1996.